Key result
Mitigating actomyosin crossbridge formation alleviates Z-disc stress and prevents hypertrophy in HCM models.
Why the study?
How dysregulated sarcomeric force production is sensed and drives pathological remodeling in familial hypertrophic cardiomyopathy remains poorly understood, hindering the development of new therapeutics.
Population
Patient-specific iPSC-derived cardiomyocytes and engineered heart tissues from 5 families bearing distinct sarcomeric mutations
Comparison
Gene editing and pharmacological interventions vs baseline or disease phenotype
Design
In vitro translational mechanobiology and computational modeling study
Authors
Loading...
Hypothesis-generating for actomyosin modulation in sarcomeric HCM; leaves open human translation.
Identifies a novel biomechanical mechanism in familial HCM where dysregulated sarcomeric force destabilizes the Z-disc MLP-mechanosensory complex, promoting hypertrophy, which can be prevented by mitigating actomyosin crossbridge formation.
Riaz et al. (2022) studied Familial hypertrophic cardiomyopathy (HCM). Gene editing and pharmacological interventions was evaluated on Mechanotransduction pathway and hypertrophic response. Mitigating enhanced actomyosin crossbridge formation via genetic or pharmacological means alleviated Z-disc stress and prevented hypertrophy associated with sarcomeric mutations in HCM models.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: